Summary of Product Characteristics last updated on medicines.ie: 16/10/2015
Stieprox Shampoo 1.5% w/w
Stieprox 15 mg/g Shampoo
Each gram of shampoo contains 15 mg/g ciclopirox olamine.
Excipients with known effect:
Contains dipropylene glycol.
For the full list of excipients, see section 6.1.
Clear, straw to light-orange coloured, viscous shampoo.
4.1 Therapeutic indications
Stieprox is indicated in the treatment of scalp disorders such as dandruff and seborrhoeic dermatitis.
4.2 Posology and method of administration
Adults and adolescents aged over 12 years:
Stieprox is only for topical application to the scalp and adjacent areas.
The hair should be wetted and sufficient Stieprox applied to produce an abundant lather. The scalp and adjacent areas should be vigorously massaged with the fingertips. The hair should then be thoroughly rinsed and the procedure repeated. The shampoo should remain in contact with the scalp for a total contact time of 3-5 minutes over the two applications.
Stieprox should be used two to three times weekly or as often as necessary for the treatment of scalp disorders. A mild shampoo can be used in between applications of Stieprox.
The recommended treatment period is 4 weeks.
The dosage instructions given above are suitable for the elderly.
The safety and efficacy of Stieprox in children under 12 years of age have not been established.
Hypersensitivity to the active substance, ciclopirox olamine, or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Stieprox is for external use only.
As with all shampoo products avoid contact with eyes. Ciclopirox olamine may cause eye irritation. In case of accidental contact with the eyes, rinse with water.
Stieprox may cause skin irritation. If irritation occurs and persists, treatment should be discontinued.
In rare instances, mainly in patients with chemically damaged (for example, due to hair dye), grey or white hair, a discoloration of the hair has been observed.
4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been preformed.
4.6 Fertility, pregnancy and lactation
The safety of ciclopirox olamine during human pregnancy has not been established. Studies in animals given oral or subcutaneous ciclopirox olamine did not reveal any developmental toxicity.
No effects during pregnancy are anticipated since systemic exposure is low.
It is not known if ciclopirox olamine is excreted in human milk. Risk to the infant is likely to be low since systemic exposure is low.
Patients should be advised to ensure that any residual product is fully washed off the breast prior to breast-feeding.
Studies in animals given oral or subcutaneous ciclopirox olamine did not reveal any impairment of fertility.
4.7 Effects on ability to drive and use machines
Stieprox has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effects
Clinical trial data
The following convention has been used for the classification of adverse events:
≥1/100 to <1/10
≥1/1000 to <1/100
≥1/10000 to <1/1000
Skin and subcutaneous tissue disorders
Application site irritation including, pruritus, burning sensation, erythema* and application site rash*
Immune system disorders
Application site hypersensitivity
Skin and subcutaneous tissue disorders
Hair colour changes
Hair texture changes*
*Since these effects are also symptoms of the underlying disease, it is expected that these adverse reactions would manifest as worsening of symptoms.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: email@example.com.
There is currently limited experience of accidental oral ingestion with ciclopirox olamine.
Management should be as clinically indicated or as recommended by the National Poisons Information Centre of Ireland. There is no specific treatment for accidental oral ingestion of ciclopirox olamine. If accidental oral ingestion occurs, the patient should be treated supportively with appropriate monitoring as necessary.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: other antifungals for topical dermatological use.
ATC code: D01AE14.
Mechanism of action
Ciclopirox olamine is a hydroxypyridone antifungal agent which is active in vitro inhibiting the growth of various fungal species including the yeast Malassezia furfur (formerly known as Pityrosporum ovale or Pityrosporum orbiculare). The latter has been implicated as a causative organism in dandruff and seborrhoeic dermatitis. Ciclopirox olamine also exhibits some anti-inflammatory activity.
Ciclopirox olamine 1.5% shampoo shows in vivo antifungal activity against Malassezia spp.
A clinical study has shown that ciclopirox olamine 1.5% shampoo significantly reduced the count of Malassezia furfur spp. in samples obtained from the scalp of subjects with dandruff and/or seborrhoeic dermatitis.
5.2 Pharmacokinetic properties
The potential for clinically significant systemic absorption of ciclopirox olamine from a wash-off shampoo containing 1.5% ciclopirox olamine is expected to be low.
Following oral administration of ciclopirox olamine to humans, affinity of ciclopirox olamine to serum proteins was found to be 96±2% in the concentration range of 0.01 to 11.0 µg/mL.
The metabolic patterns after oral and dermal application are similar. Glucuronidation of ciclopirox olamine appears to be the major form of its metabolism.
Following oral administration of ciclopirox olamine to humans, 96% of the administered dose is excreted within 12 hours. Ciclopirox olamine is excreted in urine with approximately 80% of an oral dose excreted as the glucuronide metabolite.
5.3 Preclinical safety data
Ciclopirox olamine has been in use for twenty years. It is used in leave-on topical antifungal preparations and vaginal creams. Studies have not demonstrated any prohibitive findings in reproduction toxicology, mutagenicity, carcinogenicity or phototoxicity.
A dermal carcinogenic study in mice at concentrations of 1% and 5% ciclopirox olamine formulated in polyethylene glycol 400 applied to the intact skin, twice a week, for one year, followed by a six-month non-treatment period was conducted. No tumours were observed in any of the mice at the site of application. Overall incidence of neoplasms was similar among the treated and control groups. In addition, there is no evidence that ciclopirox olamine is carcinogenic following oral or subcutaneous administration to a number of animal species.
Ciclopirox olamine did not cause gene mutation or chromosomal damage in several bacterial mutagen assays or in two mammalian assays. In a battery of in vitro genotoxicity assays with ciclopirox free acid, one assay was weakly positive. The weight of evidence provided by the in vitro and in vivo assessments suggest that ciclopirox does not present a genotoxic hazard to humans.
Reproductive studies in mice, rats, rabbits and monkeys, at doses of ciclopirox olamine 10 times that of a topical human dose, have revealed no significant evidence of impaired fertility or harm to the foetus. There is evidence that ciclopirox olamine crosses the placental barrier in animals.
6.1 List of excipients
Sodium lauryl ether sulphate 70%
Disodium phosphate dodecahydrate
Citric acid monohydrate (for pH-adjustment)
Fruitier timotei AF17050
Sodium hydroxide (for pH-adjustment)
6.3 Shelf life
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
High density polyethylene bottles fitted with polypropylene screw caps containing 20 ml or 100 ml shampoo.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
No special requirements.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
GlaxoSmithKline (Ireland) Ltd
Citywest Business Campus
Trading as Stiefel
Date of first authorisation: 5 October 2001
Date of last renewal: 5 October 2006
14 October 2015